CINCINNATI, OH--(Marketwire - January 25, 2011) -
| Highlighted Links |
clinical research |
medpace |
"We are very pleased to have Dr. Weng join us. Dr. Weng enhances Medpace's expertise in managing multi-national clinical trials in various therapeutic areas," said August Troendle, MD, President and CEO, Medpace. "His skill in managing global teams such as data services, regulatory, medical and safety, in addition to clinical operations adds to the overall capabilities of the Medpace group."
"I am very happy to join the Medpace team. Medpace has a reputation for great scientific process, clinical expertise, quality focus, and global capacity with local excellence in the markets they serve," said Dr. Weng. "I am confident that Medpace emerging markets will continue to develop local staffs to offer our sponsors new services on a global platform over the next few years."
Dr. Dan Weng brings to the Medpace management team over twenty five years of clinical experience, with seventeen years from executive positions with various clinical research organizations. Dr. Weng's extensive work in Asia, Pacific Rim, Latin America, and South Africa add to the global reach of the Medpace group. Dr. Weng has held positions of increasing responsibility, including Executive Vice President, Emerging Markets over Rest of World. He has also served as a research fellow at Harvard Medical School and the University of California working on cardiovascular clinical trial protocol design, implementation, and review.
Dr. Weng received his Doctor of Medicine degree from Tongji Medical University in China and his undergraduate diploma in human psychology from the Psychology Institute of Sino-Academy of Sciences. Dr. Weng also received his Master of Arts in Healthy Planning, Policy, and Management from Leeds University in the United Kingdom in addition to being a PhD candidate in bioengineering from Strathclyde University in Glasgow, United Kingdom.
ABOUT MEDPACE
Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services. In June 2009 Medpace was rated as the best CRO by U.S. Investigators in the 2009 CenterWatch Site Survey.
Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.
With more than 1000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, centralized imaging core laboratory management and reading from Imagepace, and medical device development from Medpace Medical Device.
Visit the Medpace website at www.medpace.com
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati:
